Restylane Volyme Lidocaine 1ml — OBT Technology for Midface Volume Restoration

Restylane Volyme Lidocaine 1ml is Galderma’s mid-firmness OBT / XpresHAn-Technology filler — designed for midface volume restoration including cheek augmentation, zygomatic projection, and chin volumising. It contains 20 mg/mL of cross-linked hyaluronic acid and 3 mg/mL (0.3%) premixed lidocaine. The product is CE marked for international markets but is not currently FDA approved in the United States.

Galderma launched a separate product, Restylane Contour, as the FDA-approved cheek augmentation filler for the US market. Volyme remains the equivalent product in the EU, UK, Asia, and most international markets. The gel formulations of Volyme and Contour are similar in indication but follow separate regulatory tracks. Practitioners ordering Restylane Volyme should verify that import and clinical use are permitted in their jurisdiction.

Both products are used for cheek and midface volume but differ in cross-linking technology. Restylane LYFT uses NASHA® Technology — biphasic, particle-based, firmer projection with the longest established history in cheek augmentation. Restylane Volyme uses OBT / XpresHAn Technology — monophasic, integrating with surrounding tissue and prioritising natural facial expression. Practitioners select LYFT for maximum structured lift, Volyme for natural movement and tissue integration.

Per Galderma clinical data, Restylane Volyme delivers up to 12 months of correction in midface volumising. Duration depends on dose, placement depth (subcutaneous vs supraperiosteal), patient metabolism, and facial movement intensity. Cheek and zygomatic placements often deliver the longer end of the duration range due to lower metabolic turnover in these layers.

OBT (Optimal Balance Technology), globally branded XpresHAn Technology, is Galderma’s monophasic cross-linking process used across Restylane Volyme, Refyne, Defyne, Kysse, and Contour. It produces a smooth, integrative gel optimised for flexibility and facial expression — distinct from the firmer NASHA Technology used in classic Restylane and Restylane LYFT.

Restylane Volyme is intended for subcutaneous to supraperiosteal placement in the midface — significantly deeper than the mid-dermal placement of Refyne and Defyne. For cheek augmentation, supraperiosteal bolus technique or fanning is commonly used. The recommended needle is 27G; many practitioners prefer a 25G or 27G blunt cannula for deeper safety in vascular zones.

Yes — chin augmentation is a common Volyme indication in markets where it is approved. In the US, Restylane Defyne carries the dedicated FDA chin augmentation approval. Outside the US, Volyme is widely used for chin volumising and profile enhancement. Off-label or off-region use is at the practitioner’s clinical discretion within scope of practice.

Yes. A common midface rejuvenation protocol uses Restylane Volyme for cheek volume in combination with Restylane Defyne for nasolabial folds, Restylane Refyne for marionette lines, and Restylane Kysse for lips. All Restylane products share the same 20 mg/mL HA base concentration and have established Galderma compatibility data.

Restylane Volyme is manufactured by Q-Med AB in Uppsala, Sweden — Galderma’s biotechnology subsidiary. The product is part of the OBT / XpresHAn Technology range and is distributed across CE-marked markets including the EU, UK, and most of Asia.

Store at 2-25 °C in original packaging, away from direct sunlight. Do not freeze. Shelf life is typically 24 months from manufacturing date when unopened. Once opened, contents must be used immediately — partial syringes cannot be retained for later use.